Phosphodiesterase 4 Inhibition Reduces Innate Immunity and Improves Isoniazid Clearance of Mycobacterium tuberculosis in the Lungs of Infected Mice
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is one of the leading infectious disease causes of morbidity and mortality worldwide. Though current antibiotic regimens can cure the disease, treatment requires at least six months of drug therapy. One reason for the long duration of therapy is that the currently available TB drugs were selected for their ability to kill replicating organisms and are less effective against subpopulations of non-replicating persistent bacilli. Evidence from in vitro models of Mtb growth and mouse infection studies suggests that host immunity may provide some of the environmental cues that drive Mtb towards non-replicating persistence. We hypothesized that selective modulation of the host immune response to modify the environmental pressure on the bacilli may result in better bacterial clearance during TB treatment. For this proof of principal study, we compared bacillary clearance from the lungs of Mtb-infected mice treated with the anti-TB drug isoniazid (INH) in the presence and absence of an immunomodulatory phosphodiesterase 4 inhibitor (PDE4i), CC-3052. The effects of CC-3052 on host global gene expression, induction of cytokines, and T cell activation in the lungs of infected mice were evaluated. We show that CC-3052 modulates the innate immune response without causing generalized immune suppression. Immune modulation combined with INH treatment improved bacillary clearance and resulted in smaller granulomas and less lung pathology, compared to treatment with INH alone. This novel strategy of combining anti-TB drugs with an immune modulating molecule, if applied appropriately to patients, may shorten the duration of TB treatment and improve clinical outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages
Schnappinger, D., Ehrt, S., Voskuil, M. I., Liu, Y., Mangan, J. A., Monahan, I. M., Dolganov, G., Efron, B., Butcher, P. D., Nathan, C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030846 · Cited by 1,420
Self-citationToll‐like receptors control autophagy
Delgado, M. A., Elmaoued, R. A., Davis, A. S., Kyei, G., & Deretic, V. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.31 · Cited by 744
Reconsidering Adjuvant Immunotherapy for Tuberculosis
Wallis, R. S. (2005) · Clinical Infectious Diseases · doi:10.1086/430914 · Cited by 121 · cited 1×
“Some evidence to support this hypothesis is available from clinical trials using immune modulators as adjunctive therapy in treatment of pulmonary TB [15,16].”
Cited by
Host-directed therapies for bacterial and viral infections
Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S., & Bartenschlager, R. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.162 · Cited by 831
Metformin as adjunct antituberculosis therapy
Singhal, A., Jie, L., Kumar, P., Hong, G. S., Leow, M. K.-S., Paleja, B., Tsenova, L., Kurepina, N., Chen, J., Zolezzi, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009885 · Cited by 547
“Some of these drugs, such as phosphodiesterase 4 inhibitors, alter tissue inflammation associated with Mtb infection, and the anti-inflammatory effects were considered beneficial (26, 38).”
BackgroundSelf-citationDynamic balance of pro‐ and anti‐inflammatory signals controls disease and limits pathology
Cicchese, J. M., Evans, S., Hult, C., Joslyn, L. R., Wessler, T., Millar, J. A., Marino, S., Cilfone, N. A., Mattila, J. T., Linderman, J. J., et al. (2018) · Immunological Reviews · doi:10.1111/imr.12671 · Cited by 343
Advancing host-directed therapy for tuberculosis
Wallis, R. S., & Hafner, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3813 · Cited by 291
Wallis, R. S., Maeurer, M., Mwaba, P., Chakaya, J., Rustomjee, R., Migliori, G. B., Marais, B., Schito, M., Churchyard, G., Swaminathan, S., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00070-0 · Cited by 262
Metadata
- Authors
- Koo, M.-S., Manca, C., Yang, G., O'Brien, P., Sung, N., Tsenova, L., Subbian, S., Fallows, D., Muller, G., Ehrt, S., & Kaplan, G.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-02-25
- Volume
- 6
- Issue
- 2
- Pages
- e17091
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1967688728
- Cited by
- 76
- References
- 3
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phosphodiesterase 4 Inhibition Reduces Innate Immunity and Improves Isoniazid Clearance of Mycobacterium tuberculosis in the Lungs of Infected Mice. https://app.cochat.ai/papers/10.1371/journal.pone.0017091
- The paper
- Koo, M.-S., Manca, C., Yang, G., O'Brien, P., Sung, N., Tsenova, L., Subbian, S., Fallows, D., Muller, G., Ehrt, S., & Kaplan, G. (2011). Phosphodiesterase 4 Inhibition Reduces Innate Immunity and Improves Isoniazid Clearance of Mycobacterium tuberculosis in the Lungs of Infected Mice. PLoS ONE. https://doi.org/10.1371/journal.pone.0017091
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.